Indo US Bio-Tech Ltd (INDOUS)
🎯 Key Takeaways
- Indo US Bio-Tech Ltd is in a phase of operational scaling with strong profitability metrics, but faces significant near-term volatility due to share price declines and governance transparency concerns. The company demonstrates robust margins and improving profitability trends, yet its financial performance is concentrated in a few large revenue periods with limited operational diversification.
- Revenue grew 26.8% QoQ to ₹33 in Q1FY27.
- ⚠️ 1) Persistent technical governance lapses, as evidenced by the SDD data loss incident, raise concerns about data integrity and compliance controls des
- Market Cap
- ₹156
- P/E Ratio
- 13.6
- P/B Ratio
- 4.04
- ROE
- 29.8%
- ROCE
- 28.6%
- Debt/Equity
- 0.33
- Promoter
- 68.3%
📖 The Story
Indo US Bio-Tech Ltd is in a phase of operational scaling with strong profitability metrics, but faces significant near-term volatility due to share price declines and governance transparency concerns. The company demonstrates robust margins and improving profitability trends, yet its financial performance is concentrated in a few large revenue periods with limited operational diversification. Management appears focused on governance compliance and technical modernization rather than aggressive growth initiatives.
📰 What's Happening
The company has approved its standalone unaudited Q1 FY26 results showing revenue growth to ₹3,311.05 crores from ₹2,604.62 crores YoY and net profit rising to ₹303.74 crores from ₹187.11 crores. Board restructuring occurred following director changes, including the appointment of Hemanshi Darsh Soni as an independent director. A technical failure in the Structured Digital Database (SDD) caused loss of historical UPSI records during Q1 FY26, though the system has been restored with enhanced controls and vendor-led root cause analysis underway. The trading window closed post-results announcement as per SEBI regulations.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 31 | 23 | 26 | 33 |
| Operating Profit | 4 | 4 | 3 | 4 |
| OPM % | 12.8% | 17.2% | 11.4% | 11.2% |
| Net Profit | 3 | 3 | 2 | 3 |
| EPS | ₹1.72 | ₹1.49 | ₹0.98 | ₹1.51 |
Revenue has shown consistent growth from ₹23 crores in Dec 2025 to ₹33 crores in Jun 2026, with operating profit margin stabilizing around 11-12% despite margin expansion observed in prior quarters. Net profit and EPS have increased sequentially and YoY, indicating improved cost management and scale benefits. However, profitability appears volatile, with OPM declining from 17.2% in Dec 2025 to 11.2% in Jun 2026, suggesting rising input costs or pricing pressures that management has not addressed in public commentary.
🔮 Management Outlook & What's Next
Management has not provided explicit forward guidance in the reviewed filings. The only forward-looking statement relates to the completion of vendor-led root cause analysis for the SDD technical glitch and implementation of periodic data verification controls. No strategic growth targets, market expansion plans, or financial projections were disclosed in the board meeting commentaries or results announcements.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2022 | Mar 2022 |
|---|---|---|
| Equity Capital | 9 | 6 |
| Reserves | 29 | 18 |
| Borrowings | 13 | 11 |
| Total Liabilities | 56 | 36 |
| Fixed Assets | 6 | 5 |
| Investments | 0 | 0 |
| Total Assets | 56 | 36 |
The balance sheet indicates a stable capital structure with low debt-to-equity of 0.33 and consistent equity levels over recent periods. Total assets have grown from ₹36 crores to ₹56 crores between March 2022 and March 2022, reflecting asset base expansion. There is no evidence of aggressive capital expenditure or deleveraging; the company appears to be funding operations through retained earnings rather than external financing.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2022 |
|---|---|
| Operating | +3 |
| Investing | -5 |
| Financing | +3 |
| Net Cash Flow | -0 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 70.2% | 70.2% | 68.3% | 68.3% |
| FII | 0.0% | 0.0% | 0.2% | 0.0% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% |
| Public | 24.1% | 23.7% | 24.5% | 24.5% |
| # Shareholders | 4,130 | 4,738 | 4,531 | 4,690 |
Promoter holding remains stable at 68.29% over the last four quarters, with no significant changes in FII or DII participation — FII ownership is minimal at 0.01-0.18%, and DII holdings are consistently zero. The number of public shareholders has slightly increased, but overall shareholding structure shows limited institutional interest. No pledging activity or share buybacks were disclosed.
⚖️ Peer Comparison — FMCG
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| HINDUNILVR | 4.45 L Cr | 29.8 | 29.8% | — | 0.00 |
| ITC | 3.32 L Cr | 16.7 | 36.0% | — | 0.03 |
| NESTLEIND | 2.60 L Cr | 68.1 | 99.2% | — | 0.00 |
| VBL | 1.45 L Cr | 43.0 | 21.5% | — | 0.10 |
| BRITANNIA | 1.18 L Cr | 45.5 | 54.1% | — | 0.27 |
| LENSKART | 1.14 L Cr | 171.2 | 11.9% | — | 0.03 |
| MARICO | 1.05 L Cr | 55.3 | 54.2% | — | 0.08 |
| TATACONSUM | 94,808 | 58.0 | 10.2% | — | 0.10 |
| GODREJCP | 89,022 | 46.5 | 17.8% | — | 0.33 |
| DABUR | 68,475 | 34.7 | 21.3% | — | 0.09 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) Persistent technical governance lapses, as evidenced by the SDD data loss incident, raise concerns about data integrity and compliance controls despite corrective measures. 2) Low institutional ownership and minimal foreign participation suggest limited investor confidence or coverage. 3) Margin compression in the latest quarter, with OPM declining to 11.2% from 17.2% in the previous quarter, indicates potential operational headwinds not yet addressed by management. 4) Share price volatility and negative 1Y return (-46.27%) reflect market skepticism about near-term recovery despite improving financials.
📋 Recent Filings
- Announcement2026-09-28Indo US Bio-Tech Ltd announced that its insider trading compliance window will close on October 1, 2026, ahead of the unaudited Q2 and H1 2026 financi…
- 🔴 annual report2026-09-05Indo US Bio-Tech Limited reported a 15% revenue increase to **[amount context mismatch] crores** for FY2025-26, driven by strong seed sales, while net…
- 🟡 Board Meeting2026-09-05Indo US Bio-Tech held its 22nd AGM on September 30, 2026 via video conferencing, adopting the 2025-26 audited financials and appointing Priyanka Samar…
- 🟡 Board Meeting2026-09-05Indo US Bio-Tech held its 22nd AGM on September 30, 2026 via video conferencing, adopting the 2025-26 audited financials, reappointing Director Priyan…
- 🟡 Board Meeting2026-09-05Indo US Bio-Tech announced its 22nd Annual General Meeting will be held on 30 September 2026 via video conference, with book closure on 23 September. …
- 🔴 Financial Results2026-08-12Indo US Bio-Tech Limited approved its standalone unaudited financial results for Q1 June 2026, showing revenue of **₹3,311.05 crores** and net profit …
- 🟡 Board Meeting2026-08-12The board approved unaudited Q1 FY26 results showing revenue of **₹3,311.05 crores**, up from **₹2,604.62 crores** in Q1 FY25, with net profit of **₹3…
- 🔴 Insider Trading2026-07-21Indo Us Bio Tech Limited disclosed a technical failure in its Structured Digital Database (SDD) that caused loss of historical UPSI records during Q1 …
- 🟡 Board Meeting2026-07-15Indo Us Biotech Limited announced a revised board committee structure effective from 21 April 2026, following director appointments and resignations a…
- 🟡 Board Meeting2026-07-10The board reconstituted its Audit, Nomination and Remuneration, and Stakeholders Relationship committees following the appointment of Hemanshi Darsh S…
🧠 Analyst's Read
Indo US Bio-Tech is transitioning from a stable but stagnant operational base toward scalable growth, but its trajectory remains uncertain due to governance transparency issues and margin volatility. Investors should monitor management's ability to restore investor trust, resolve technical compliance risks, and demonstrate sustainable margin expansion beyond one-off gains.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-29.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when INDOUS files new disclosures
Track INDOUS filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track INDOUS — FreeFree account · 2 AI queries/day